Investor Relations
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases.
As of 12 October 2026, EXACT Therapeutics is a privately held company.
Shareholder information about the delisting
Practical information for shareholders, including information about the delisting process.
Sign up for shareholder updates
Receive the latest company news, financial updates and other relevant shareholder information by email.
Latest update
First half 2026 interim report
3 September 2026
EXACT Therapeutics announced its first half 2026 interim results.
Reports, presentations and webcasts
2026
| Period / date | Financial report | Presentation | Webcast |
|---|---|---|---|
| H1 2026 | Interim report | — | — |
| 4 June 2026 | — | Delisting webcast presentation | View webcast |
| 11 February 2026 | — | Global investor call | — |
| 5 February 2026 | — | Company presentation | — |
2025
| Period / date | Financial report | Presentation | Webcast |
|---|---|---|---|
| FY 2025 | Annual report | — | — |
| H1 2025 | Interim report | — | — |
2024
| Period / date | Financial report | Presentation | Webcast |
|---|---|---|---|
| FY 2024 | Annual report | — | — |
| H1 2024 | Interim report | — | — |
| 4 December 2024 | — | Private placement investor presentation | View webcast |
| 8 October 2024 | — | CMR Symposium presentation | — |
| September 2024 | — | ISTU presentation | — |
| 18 March 2024 | — | BIO-Europe presentation | — |
Older reports
General meetings
2026
2024
Older AGM
Corporate governance
Investor relations contact
John M. Edminson — CFO
EXACT Therapeutics
john.edminson@exact-tx.com